Specificity of Therapy Selection for Patients with Nontuberculous Lung Mycobacteriosis
E. B. Vladimirova, 
E. I. Shmelev,
N. N. Makaryants,
A. S. Zaitseva,
S. A. Kasimtseva,
T. G. Smirnova
E. I. Shmelev,
N. N. Makaryants,
A. S. Zaitseva,
S. A. Kasimtseva,
T. G. Smirnova https://doi.org/10.31550/1727-2378-2023-22-2-57-61
Abstract
Aim: To identify the incidence and the characteristics of adverse reactions, to mitigate them, and to determine possible adjustments in antimicrobial therapy.
Design: Observational retrospective long-term study.
Materials and methods. We examined 125 patients with nontuberculous lung mycobacteriosis. 73.6% of cases had concomitant diseases.
Results. The therapy for nontuberculous mycobacteriosis was prescribed in 115 patients, depending on drug susceptibility, and included at least 3 drug products. 31.3% of patients had adverse reactions; one third of these patients had allergic reactions. Hepatotoxic reactions were recorded in 16.5% of cases, cardiotoxic — in 12.2%, ototoxic — in 10.4%, optic neuritis was diagnosed in 5 % of cases. In 31.3% of cases, the therapy was adjusted, in 13.9% of cases, the therapy was reviewed and alternative treatment was offered. The complete antibacterial course was prescribed to 79 (68.7%) patients.
Conclusion. The therapy for nontuberculous mycobacteriosis should be selected in inpatient settings with laboratory and functional monitoring.
About the Authors
E. B. Vladimirova
Central Scientific and Research Institute of Tuberculosis
Russian Federation
Russian Federation
2 Yauzskaya Alley, Moscow, 107564
E. I. Shmelev
Central Scientific and Research Institute of Tuberculosis
Russian Federation
Russian Federation
2 Yauzskaya Alley, Moscow, 107564
N. N. Makaryants
Central Scientific and Research Institute of Tuberculosis
Russian Federation
Russian Federation
2 Yauzskaya Alley, Moscow, 107564
A. S. Zaitseva
Central Scientific and Research Institute of Tuberculosis
Russian Federation
Russian Federation
2 Yauzskaya Alley, Moscow, 107564
S. A. Kasimtseva
Central Scientific and Research Institute of Tuberculosis
Russian Federation
Russian Federation
2 Yauzskaya Alley, Moscow, 107564
T. G. Smirnova
Central Scientific and Research Institute of Tuberculosis
Russian Federation
Russian Federation
2 Yauzskaya Alley, Moscow, 107564
References
1. Ergeshov A.E., Shmelev E.I., Kovalevskaya M.N. et al. Nontuberculous mycobacteria in patients with respiratory diseases (a clinical study). Pulmonologiya. 2016;26(3):303–308 (in Russian). DOI: 10.18093/0869-0189-2016-26-3-303-308
2. Vladimirova E.B., Shmelev E.I., Zaytseva A.S. et al. Non-tuberculous mycobacteriosis of the lungs — diagnostic possibilities in the practice of the pulmonologist. Therapeutic Archive. 2019;91(11):31–36 (in Russian). DOI: 10.26442/00403660.2019.11.000306
3. Griffith D.E., Aksamit T., Brown-Elliott B.A. et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. AJRCCM. 2007;175(4):367–416. DOI: 10.1164/rccm.200604-571ST
4. Zaytseva A.S., Stepanyan I.E., Shmelev E.I. Non-tuberculous mycobacteria pulmonary diseases: treat or observe? Respiratory Organs Diseases (Suppl. Consilium Medicum). 2019;(1):35–38. (in Russian). DOI: 10.26442/26190079.2019.190494
5. Degtyareva S.А., Shmelev E.I., Stepanyan I.E. et al. Long-term fever as a manifestation of drug intolerance in patients with nontuberculous pulmonary mycobacteriosis (clinical case). Bulletin of modern clinical medicine. 2019;12(3):73–77. (in Russian) DOI: 10.20969/VSKM.2019.12(3).73-77
6. Kamii Y., Nagai H., Kawashima M. et al. Adverse reactions associated with long-term drug administration in Mycobacterium avium complex lung disease. Int. J. Tuberc. Lung Dis. 2018;22(12):1505–1510. DOI: 10.5588/ijtld.18.0171
7. Chen J., Zhao L., Mao Y. et al. Clinical efficacy and adverse effects of antibiotics used to treat mycobacterium abscessus pulmonary disease. Front. Microbiol. 2019;10:1977. DOI: 10.3389/fmicb.2019.01977
8. Balavoine C., Blanc F.X., Lanotte P, et al. Adverse events during treatment of nontuberculous mycobacterial lung disease: do they really matter? Eur. Respir. J. 2018;52:PA2664. DOI: 10.1183/13993003.congress-2018.PA2664
9. Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200–1205. DOI: 10.1001/jama.279.15.1200
Review
For citations:
Vladimirova E.B., Shmelev E.I., Makaryants N.N., Zaitseva A.S., Kasimtseva S.A., Smirnova T.G. Specificity of Therapy Selection for Patients with Nontuberculous Lung Mycobacteriosis. Title. 2023;22(2):57-61. (In Russ.) https://doi.org/10.31550/1727-2378-2023-22-2-57-61
Views:
14
Email this article 